Pneumonitis risk from pembrolizumab in non-small cell lung cancer: Interstitial abnormalities matter, and so does treatment
{{output}}
Background: Immune checkpoint inhibitors (ICIs) such as pembrolizumab have improved outcomes in non-small cell lung cancer (NSCLC), but immune-related pneumonitis remains a clinically important concern. While interstitial lung di... ...
